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Steps to Improve Transfusion Practices for
Patients With Sickle Cell Disease and Thalassemia
Background
Georgia has one of the nation’s largest populations of individuals with sickle cell disease (SCD) and thalassemia. For
many of these individuals, blood transfusion may be needed on a regular, intermittent, or emergency basis. In order to
avoid serious complications, like alloimmunization and iron overload, among patients who receive multiple transfusions in
their lifetime, patients, physicians, and blood bank personnel need to know and follow specific, recommended practices.
The Centers for Disease Control and Prevention funds Georgia’s REdHHoTT project to reduce complications of
therapeutic blood transfusion in SCD and thalassemia. As part of this work, the Georgia Health Policy Center surveyed
Georgia hospital transfusion services (blood banks) to gauge adherence to currently recommended practices and to
inform improvement strategies.

Hospital Blood Bank Survey Results
Thirty-five institutions responded (71%), of which
32 reported experience transfusing SCD patients
and 11 reported experience transfusing thalassemia
patients. Responding institutions that are classified as
comprehensive sickle cell treatment centers (n = 3) or
thalassemia treatment centers (n = 1) follow applicable
practice recommendations. Results varied among the
remaining hospitals, as illustrated below.

*

Full results were published in Fasano, R. M., Branscomb, J., Lane, P., Josephson,
C., Snyder, A., & Eckman, J. (2019). Transfusion service knowledge and
immunohaematological practices related to sickle cell disease and thalassemia.
Transfusion Medicine Reviews, https://doi.org/10.1111/tme.12580

Contact the Georgia Health Policy Center to request
grand rounds or consultation with specialists in
thalassemia and SCD management, transfusion
medicine, and blood bank practices.
Email: BloodDisorders@gsu.edu
Watch a continuing education course, Reducing
Complications of Therapeautic Blood Transfusion in
Sickle Cell Disease at ghpc.gsu.edu/cme
Learn more about REdHHoTT visit bit.ly/GHPC_SCDC

404.413.0314
ghpc.gsu.edu
ghpc@gsu.edu
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Adherence to selected SCD transfusion recommendations1 among noncomprehensive treatment centers
Perform extended red blood cell phenotyping and prophylactically match units, including for ABO/Rh(D)
and at least C, c, D, E, e, and Kell, to reduce likelihood of patient developing antibodies

71%

Provide sickle cell trait–negative red blood cells.

100%

Obtain patient transfusion history including locations of prior transfusions; ask blood bank to contact
hospitals where patient reported receiving previous transfusions to obtain transfusion information.
• Use a reliable method to identify SCD patients prior to transfusion, such as a required questionanswer field on type, screen, or crossmatch orders

33%

• Have a routine system in place to identify SCD patients who may have received transfusions
elsewhere

77%

Adherence to selected thalassemia transfusion recommendations2 among nonthalassemia treatment centers
Perform extended red blood cell antigen typing that includes at least C, c, D, E, e, and Kell and transfuse
with units prophylactically matched for ABO and Rh (C, c, D, E, e) and Kell.

20%

Before each transfusion, run a full cross-match and screen for new antibodies, or in centers that meet
regulatory requirements, an electronic cross-match.

50%

Commonly Cited Challenges

Respondents were given an open-ended question to describe challenges they face regarding transfusing patients with
hemoglobin disorders. The following challenges were cited multiple times:
• Lack of standard policies/procedures (within a health system or across hospitals) for red blood cell phenotyping
and blood product matching
• Securing appropriately matched red blood cell units for alloimmunized patients
• Lack of standardized procedures for notifying transfusion services that a patient has either SCD or thalassemia
• Obtaining a reliable and complete transfusion and antibody history across multiple hospital systems

What Providers Can Do
• Review the full report on this study and the practice recommendations
• View a web-based video series for clinicians on transfusion recommendations for SCD, with free continuing medical
education and continuing nursing education credits provided through CDC: ghpc.gsu.edu/cme
• View a recorded webinar series for sickle cell patients and caregivers on avoiding transfusion complications, as part
of the Sickle Cell Community Consortium’s Warrior University: sicklecellconsortium.org/warrior-u-transfusions
• Contact the Georgia Health Policy Center to request grand rounds or consultation with specialists in thalassemia
and SCD management, transfusion medicine, and blood bank practices as part of the REdHHoTT project. Email
BloodDisorders@gsu.edu
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